Clinical Trial Update: A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating elezanumab added to standard of care in progressive multiple sclerosis has completed with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Elezanumab (elezanumab)

Snippet

Sponsor: AbbVie | Conditions: Multiple Sclerosis (MS) | Phase 2 | Status: COMPLETED | Results posted: 2023-12-21